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Malignant Melanoma is considered the most dangerous skin neoplasia for its 
potential to invade distant tissues and its associated mortality. Its incidence is 
considered epidemic. 
Mitotic rate was recently introduced in the AJCC guidelines as the 2
nd
 most 
important prognostic factor for thin stage I melanomas, after tumoral thickness, as it 
strongly correlates with a lower survival rate. Together with ulceration, this variable 
changes the classification of thin tumors (≤1mm) from T1a to T1b, if at least one 
mitosis/ mm
2
 is present. This implies an alteration in patients’ management and 
treatment. It has been a target of discussion for its accuracy among clinicians and 
interobserver disparities. The cutoff of one mitosis as also been targeted, since mitotic 
figures can be found in benign lesions, particularly when immunohistochemistry is 
used. 
Mitotic rate has been used to refer patients to sentinel lymph node biopsy, which 
has also been a disagreement point. Immunohistochemistry in mitoses detection is still 
under investigation but it is proved to facilitate the observation, although having some 
objections. 
Standardization is essential to a more reliable method and adequate patient’s 
maneuver. 
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Melanoma Maligno é considerado a neoplasia da pele com maior perigo, pelo seu 
potencial de invasão de tecidos distantes e mortalidade associada. A sua incidência é 
considerada epidémica. 
O índice mitótico foi recentemente introduzido nas recomendações da AJCC 
como o 2º factor de prognóstico mais importante para os melanomas finos de grau I, 
logo após a espessura tumoral, por se correlacionar com uma diminuição da taxa de 
sobrevida. Juntamente com a ulceração, esta variável altera a classificação dos tumores 
finos (≤1mm) de T1a para T1b, se pelo menos uma mitose/mm
2
 estiver presente. Isto 
implica uma alteração na gestão e tratamento dos doentes. Tem sido um alvo de 
discussão devido à fiabilidade entre clínicos e disparidades entre observadores. O 
“cutoff” de uma mitose tem também sido visado, já que as imagens de mitoses podem 
ser encontradas em lesões benignas, particularmente se forem usadas técnicas de imuno-
histoquímica. 
O índice mitótico tem sido utilizado para referenciar doentes para biópsia de 
gânglio sentinela, o que também tem sido um ponto de discórdia. A utilização de 
imuno-histoquímica na deteção de mitoses continua sob investigação, no entanto está 
provado que facilita a observação, embora haja algumas objeções a ter em conta. 
Uniformizar a técnica é essencial para um método mais fiável e uma abordagem 
adequada dos doentes. 
Palavras-chave: Melanócito; Melanoma; Mitose (s); Índice Mitótico; Prognóstico; 







A review of the bibliography was carried out about a mediatic theme that is 
Malignant Melanoma. Mitotic rate was chosen for its integration as a prognostic marker 
in the last AJCC guidelines published in 2009. It is a thematic that involves discussion 
and disagreement among clinicians and, particularly, pathologists. 
Therefore, we agglomerated and discussed the theme exposed in recent 
bibliography, conjugating it with previous knowledge and supposedly acquired facts, in 
order to achieve a deeper acquaintance in how to deal with mitoses in malignant 
melanoma’s prognosis, the process of their acquirement and the consequences they can 
lead to. We end by suggesting that new studies are accomplished to clarify the methods 
for mitotic rate applications in this skin neoplasia. 
 
Methods 
The review of the literature was carried out using “Pubmed” and “repositorio.ul” 
for articles between 2000-2016 and afterwards between 1945-2016. The terms used for 
the search included: melanoma, histopathology, mitosis (or mitoses), mitotic index (or 
mitotic rate), benign nevus (or nevi), prognosis, sentinel lymph node biopsy and 
immunohistochemistry. 
The most relevant abstracts were assessed for information integrating mitotic rate 
and malignant melanoma, the process for their acquisition and their possible 
consequences. 
Additionally, related articles and the reference lists of the selected ones were also 
used as sources for further potential information. 
 
Results 
Malignant Melanoma - General Considerations  
Melanocytes, cells from which melanocytic lesions develop, originate from 
ectoderm in neural crest, sharing some characteristics with neuronal cells. Melanocytes 
in humans exist in multiple regions of the human body besides the skin and hairs, 
namely iris, inner ear, adrenal gland, gastrointestinal, genitourinary and even central 
nervous system. For this reason, malignant melanoma (MM) can occur in any of these 
7 
 
places. Some studies discovered distinct properties and DNA modifications depending 
on the anatomical location of the lesion, no matter what its histologic group was 
1,2
.  
MM is a malignant neoplasia derived from melanocytes, usually beginning in the 
epidermis. While confined to epidermis, MM is considered in situ and it lacks potential 
for metastasis; this phase is called radial growth. Afterwards it might penetrate dermis, 
initiating the vertical growth and acquiring the capacity to metastasize into distant 
organs, since in opposition to epithelium, these tissues are highly vascularized, with 
blood and lymph vessels 
1,2
. 
It is considered the most malignant skin neoplasia for its potential to invade, not 
only locally but mainly distant tissues, by vascular or lymphatic dissemination 
2,3
. 
MM originate more commonly de novo, directly from a normal melanocyte or, on 
the contrary, 20-25% may transit from a previous benign lesion, including congenital 
nevi, or even from an area of an old sunburn or previous radiotherapy 
2,4
. They can also 
appear in association to HIV infection, lymphoma or after transplant 
2
. 
Melanoma is considered the 7
th
 more common cancer in the USA 
5
, accounting for 
approximately 5% of all new cancers in 2014 
6
. Regarding skin cancers, it corresponds 
to less than 7% of all but accounts for about 75% of deaths from these malignancies 
1
. 
According to recent studies, its incidence has been increasing in a large scale for 
the last few decades, being even considered by some an epidemic cancer, nowadays 
reaching a rate of almost 40 per 100.000 in Australia
2
 and 26,3 per 100.000 in the 
USA
7
. It was estimated that almost 74.000 new cases of MM appeared in 2015 and 
there were around 10.000 new deaths caused by this cancer 
8
. In Europe, MM’s 
incidence was predicted to be around 12-16:100.000 inhabitants, in women and men 
respectively. However, it depends if it is in the north or south, being higher in Central 
and Eastern European countries 
9
. In Mediterranean countries incidence varies from 3 to 
5:100.000 per year and in the Nordic ones from 12 to 25:100.000 (and rising) 
10
. There 
is no accurate estimation for Portugal individually but we integrate the Mediterranean 
countries and correlate with the other European southern countries such as Spain and 
Italy. Melanoma is 20 times more common in Caucasians, mostly in sun exposed skin 
and, particularly in areas of intermittent sun exposure, namely trunk in men and legs in 
women, and after sunburns in childhood 
2,11
. 
The epidemic concept introduced in the previous paragraph is a discussion target 
between clinicians. Some argue it is in part due to overdiagnosis by more free 
8 
 
screenings, in context of increased alert among the population, aided by media cover. 
Also, it may be a result of a more concerned reporting after detecting and excising a 
lesion or, on the other hand, on a propensity to diagnose as malignant doubtful lesions, 
mislead by fear of missing some dangerous lesion. Still, some admit there might have 
been a truly increment in MM incidence considering two facts: the preferential 
incidence in the elderly and the higher average life expectancy of the population. In the 
end, the main reason pointed is the hard distinction from other benign pigmented lesions 
12
. 
Recent studies prove that more than one half of MM are considered thin, with 
Breslow depth <1mm and a very good prognosis: 10-year survival of 83,1-96,5% 
7,13
. 
Incidence varies according to risk factors, which can be divided in personal and 


















Every type of melanoma can develop metastases, even the thin ones that 
supposedly had a great outcome. That is why scientists and clinicians have been trying 






Table 1: Personal Risk Factors 
Age 
Phototype/ Sun susceptibility 
Personal/ Family history of MM 
UV-rays exposition 
(chronical: lentiginous MM; 
intermittent: superficial spreading) 
Precursor lesions 
(number of dysplastic, congenital 
and common nevi) 
Trauma 







Still today, MM diagnosis relies in the correlation among clinic and microscopic 
Hematoxylin-Eosin (H&E) stained observations, representative of the whole tumor 
2
.  
Initially the lesion has homogeneous color, regular borders and smooth 
superficies. It is indispensable to promptly set differential diagnosis between other dark 
skin tumors, even pigmented basal cell carcinomas 
1,2
. Later on, if the lesion is a MM, it 
will probably change and gain various tones, irregular borders and rough superficies, 
presenting atrophic, ulcerated or even warty zones. Usually ABCDE rule is used to help 
the interpretation of these malignant lesions. The letters of the acronym correspond to 
“Asymmetry” of the lesion, “irregular Borders”, “different Colors”, “Diameter larger 
than 6 mm” and “Evolving and rapid growth” 
14,15
. However, some critics have been 
made to diameter, as it looks arbitrary; smaller lesions can also be diagnosed as MM. It 
has been considered changing to “Dark” instead 
14
. 
Besides, other minor signs are used, such as pruritus, hypopigmentation, 
inflammation, hemorrhage, ulceration, or just the fact that is a lesion distinct from all 
other nevi in that person – “ugly duckling signal” 
2
. 
Usually MM arises in people who are around 40 years old or more, with lower 
phototypes. However, the greatest impact in mortality is seen at the average age of 20 to 
40 years old 
8
. Exceptionally, they can appear during childhood or puberty 
2
. They tend 
to grow and invade the dermal-epidermal junction, gaining power to spread and 





Usually, malignant tumors are staged evoking TNM classification: primary Tumor 
(T), lymph Node metastasis presence and number (N) and presence of local or distant 
Metastasis (M), separating it in I-II when exclusively cutaneous, III with loco-regional 
metastases and IV when distant metastases exist. This is a classification useful to make 
clinical decisions, having treatment and prognosis in mind. It is of high importance to 
have a standardized staging for tumors, allowing to offer the best diagnosis and 
therefore treatments to cancer patients 
17
. 






Since at least 4 decades, classification of primary cutaneous melanomas was made 
considering invasion depth into the dermis/ subcutis or Clark level, stratifying tumors 
between T1 and T4 levels. Clark level system divides in 5, from level I when the lesion 
is confined to the epidermis and its adnexal structures like follicles and glands (in situ 













Other important variables in the prognosis include 
2,21
:  
 Breslow thickness: MM depth in mm, vertical measure between the high 
granular zone of epidermis above the tumor (or base of ulceration), until the deepest 











 Ulceration: complete non-traumatic loss of the epidermis created by the tumor 
located underneath; undoubtedly worsens the prognosis. 










Figure 1: Clark Level I-V 




 Regression: usually the area is clinically characterized by depigmentation. It 
occurs after some areas of the lesion are destroyed by memory lymphocytes, shifting 
melanocytes for scar tissue, telangiectasias and/ or melanophages. This could mean 
the tumor was previously thicker, which would supposedly worsen the prognosis. 
However, in a recent study, regression was associated with tumor-directed T-cell 
response, which improved prognosis 
22
. 
 Tumor-infiltrating lymphocytes (TIL): presence of lymphocytes and/ or plasma 
cells around or inside the tumor. Dense TIL infiltrate has been associated with an 
excellent prognosis, independently of other adverse variables 
23
.  
  Vascular or lymphatic invasion.  
 
Tumor Mitotic Rate (TMR) as a prognostic factor 
In 2009 the melanoma staging system was substantially revised and some changes 
with consequences related to the approach to patients were published by the American 
Joint Commission on Cancer Staging Committee (AJCC). Mitotic rate (MR) was added 
as a new element, substituting Clark level, after demonstrated to be an important and 
independent prognostic factor. Mitotic index is, therefore, a quantitative measure of 
cellular proliferation in primary melanoma. Histologically, it is defined as the number 





Mitoses can be defined by an absence of the nuclear membrane in the end of 
prophase and by the presence of condensed chromosomes (chromatin’s extensions), 
either clotted in the beginning of metaphase, arranged in a plane in metaphase or 
anaphase, or even in separate clots in telophase 
24,27
. There is also an absence of a 

















It is important to differentiate dermal from epidermal component in this analysis, 
since mitoses in epidermis only have diagnostic value, being irrelevant to prognosis 
29
. 
However, for at least 30 years, it has been known that a high proliferative rate 
corresponds to an adverse prognosis 
20
. Recently, it was demonstrated that an increased 
mitotic rate correlated strongly with lower survival rates, independently of the tumor 
thickness 
21,26,30,31
. However, it also correlated with increasing tumor thickness and 
ulceration, meaning thicker MMs have higher MRs 
26,28,32
. Some tried to show a 
connection with sentinel lymph node positivity 
30
.  
MR was then considered the second most powerful predictor of survival, after 
Breslow tumor thickness, particularly among patients with thin melanomas, even 
exceeding ulceration 
3,17,19,21,26
 . It means the tumor is growing and can metastasize 
faster, behaving more aggressively 
3,26
. In fact, the AJCC classification referred mitotic 
rate was only relevant for staging thin melanomas 
19
. Nonetheless there are studies 
showing it is also appropriate for treatment decisions in thick tumors 
17
. 
The most significant correlation with survival was identified at a threshold of at 
least one mitotic figure per square millimeter, especially for thin melanomas. When 
mitoses are not found, it is recommended to report as 0 mitoses/mm
2





. It was also proved that mitotic index is highly predictive when it 




For patients with T1 melanoma the three most powerful predictors of survival are 
now considered tumor thickness of Breslow, mitotic rate/ index and ulceration. These 
three characteristics should be present in the pathology report after lesion biopsy 
21
. 
Depth of invasion (level of Clark) was proved not to be statistically relevant when the 
last two were included in the analysis. Accordingly, it was defined that mitotic rate 
would replace Clark level of invasion as a primary criterion for defining T1b melanoma, 
due to ineffectiveness of Clark level in a lesion without mitogenicity 
16,21,33
. 
In this context, T1a melanomas are restricted to those ≤1.0mm of thickness, 
without ulceration or a mitotic rate of 0/mm
2
. On the other hand, T1b is defined as those 
≤1.0 mm of thickness and, at least, one mitotic figure per mm
2
 or tumor 
ulceration
17,19,26,34
. Clark level is only used for staging when mitotic rate cannot be 






Therefore, MR, together with ulceration, currently distinguish between T1a and 
T1b stage, and thus between IA and IB in TNM scale 
21
. According to this classification 
implemented in 2009, in a non-ulcerated lesion, a single dermal mitotic figure is 
sufficient to change the tumor prognosis and patient management 
13,17,19,33,35
. The most 
immediate impact in 10-year survival prognosis for patients with thin melanomas is the 
decrease from 95% to 88% in T1a and T1b, respectively 
19,35,36
. 
In regard of T2 melanomas, there is still a lot to prove. There are some recent 
studies trying to understand if elevated mitotic index is related to sentinel lymph node 
positivity, recurrence of the disease or even its independence from other factors. Baker 
et al in 2015 showed MR ≥1/mm
2 
remains an important risk factor in this group of 
relatively thicker melanomas. In his study, MR was related to disease recurrence in 
some specific conditions, such as no ulceration. Moreover, it was associated with lower 
time until recurrence in patients with negative sentinel lymph node analysis. It appeared 
MR lost significance in predicting sentinel lymph node positivity as the thickness 
increased, hence having a higher impact for T1 and some T2 melanomas. However, 
undoubtedly, MR was strongly associated with death risk, even in thicker tumors. Baker 
et al showed higher MR associates with worse survival (proved for index higher than 20 
mitoses/ mm
2
, although only a small amount of patients have an index this high). The 
influence of higher MR in recurrence and overall survival is independent from age 
6
. 
In this context, it is important to understand how mitoses are counted. It is 
recommended by the AJCC that this rate is determined by the “hot spot approach”. 
Frishberg, D. (2001) and Weyers, W. (2009) described the so-called “hot spot” 
technique as the area in the vertical growth phase containing most mitotic figures. After 
counting the mitoses in the hot spot, it is extended to adjacent fields until an area 
corresponding to 1 mm
2
 is achieved. If no “hot spot” is found, and mitoses are randomly 
scattered throughout the lesion, several randomly chosen areas should be considered, 
summed, and the mitotic rate listed as the average. In tumors with invasive component 
of ≤1 mm, a rate per mm
2
 may be extrapolated 
20
.  
In practice, usually 3-5 high power fields are evaluated, in a 40x magnification, 
depending on the size of microscopy ocular field, and then mitotic rate is presented in 
absolute numbers. Should integrate the accounting only dermal mitoses and 
unequivocally from melanocytes, without exhaustive section of the melanoma 
16,33
. This 





Difficulties identifying melanocytic mitotic figures include the following: 
discrimination of melanocytes from keratinocytes can be difficult in the dermo-
epidermal junction; in heavily inflamed lesions, lymphocytic infiltrate intermixes with 
melanocytes and they can hardly be distinguished from each other; in heavily 
pigmented lesions mitotic figures can easily be overlooked in H&E staining; in thin 
melanomas ≤1mm
2
 the space is limited and it becomes complicated to discern which 
cell is undergoing mitosis 
17,30
.  
It is also important to be aware of how extensively one should examine the tumor 
section, particularly in thin melanomas, group in which the great majority report only 1 
or 2 mitoses per square millimeter. Searching few sections may lead to subclassification 
of a pT1b tumor into the pT1a category. On the other hand, when a thorough 
examination of the whole tumor is performed, there is no certainty about the relevance 
of one mitotic figure found in those conditions 
33,35
. 
AJCC guidelines do not recommend an exhaustive search for mitoses 
26,34
, 
supposedly limiting the sections in two 
13
. It is also discouraged to preserve tissue for 
further testing, namely molecular 
32
. There is a fluctuation in the number of mitotic 
figures across various sequential sections, enhancing the importance of evaluating more 
than just one section per lesion. In 2014 a study suggested 3 to 5 sections improved the 
accuracy of mitotic index detection 
32
. In 2015, Shin & Tallon ought to prove which 
range of tumor tissue samples had more significance for the staging criteria, reaching 
the number of 3. They also came across data that showed wide differences in number of 
tissue samplings cut for various pathologists, between or even within centers, 
concluding there is no standardization for this assessment, which can, again, lead to 




Do mitoses always mean malignancy? 
Various studies have revealed there is discordance among different pathologists 
when it comes to distinguish between thin melanoma, dysplastic and atypical nevi and 
even ordinary benign lesions. Often this distinction is not so easy to make between MM 
and other pigmented lesions, which can present themselves with characteristics typically 
seen in malignant ones 
12
. This is problematic regarding the consequences to patients. 
Those who erroneously got the melanoma diagnosis have follow-up programs for years, 
pulling-out life quality. On the other hand, those who are not diagnosed, may not get 
15 
 
access to the optimal treatment for their cancer, namely sentinel lymph node biopsy 




Back in 1949, Lund and Stobbe studied 200 nevi. They found mitotic figures in 
6,5% of the nevi and almost 80% (10 in 13 nevi) appeared in the first two decades of 
life 
37
. Usually, there is a higher dermal melanocytic mitotic rate in younger people 
7,38
. 
In 2009, Jensen et al. also agreed that, as nevi can grow, mitoses are expected to 
happen. They studied 157 randomly selected conventional nevi and 4% of them 
exhibited mitotic figures 
39
. 
In a study about spitzoid lesions the authors concluded mitoses were rare in 
spitzoid nevi, although being present and even atypical in some cases. Moreover, deep-
dermal mitoses were found, not only in spitzoid melanoma (malignant Spitz tumor) but 
in atypical spitzoid tumor as well, being the latter a transitional lesion 
40
. Some 
characteristics clearly associated with worse prognostic for MM, such as positive 
sentinel lymph node, are related to an indolent course in spitzoid lesions, including 
atypical Spitz tumor. Moreover, factors often used to predict the tumor behavior, are not 
useful in these lesions 
41
. 
Another study performed in 2014 came across the idea that in deep penetrating 
nevi, even though mitoses are rare, some sparse figures (0 – 1.2/mm
2
) can appear. This 
lesion doesn’t have a regular and uniform morphology, frequently showing histological 
characteristics of MM, namely cytologic atypia and random nuclear pleomorphism, 
especially in the deepest regions 
42
.  
Some other studies showed higher MR in benign lesions than in thin melanomas, 




Culpepper, Granter & McKee (2004) wrote nevi apparently benign are commonly 
mitotically inactive. Nonetheless they may have a sporadic mitotic figure and it should 
not worry the observant, considering mitosis was incidental and occasional, without 
clinical impact, since all the other characteristics of the lesion pointed to innocence 
(symmetry, maturation, no nuclear transformation). A mitotic figure can be present in 
case the nevus is growing, which happens in benign lesions, although slower and in a 
lower rate, when comparing to malignant tumors. However it can also happen in a 
developing melanoma, associated with a previous existent common nevus. In this case 
16 
 
the question arises: should one consider this lesion a malignant melanoma and 
categorize it as T1b due to that one mitosis, without taking into account all the other 
features which might point to benignity? 
4
 We would promptly answer: “No”. 
Usually melanoma has more mitoses and higher cellular and nuclear atypia, 
contrasting with benign lesion, where mitotic figures are rare and atypia is absent. That 
is why borderline melanocytic lesions are the most difficult to catalog, even for 
experienced pathologists, as they tend to mix up all these aspects used to differentiate 
benign from malignant tumors 
42
. For instance, dysplastic nevi sometimes considered 
“severely dysplastic” are usually what should be called MM or MM in situ, arising from 
a benign lesion 
43
.  
Regarding mitoses, it is now obvious they are not capable of distinguish certainly 
between benign and malignant lesions. Even hyperplastic skin may show mitoses, 
feature usually associated with malignant tumors 
40
. If lesions are exhaustively 





Sentinel Lymph Node Biopsy 
Sentinel Lymph Node Biopsy (SLNB) has been used to determine prognosis for 
doubtful lesions, which have been linked to high probability of metastases. Some even 
argue lymph node positivity “is the most important independent prognostic factor for 
survival in primary melanoma ≥1mm in thickness” 
21,22,25,44
. The fact is, although it has 
not been proved that early surgical removal of invaded lymph nodes increases long term 




Being important for prognosis, mitotic rate may as well be useful to determine 
which MM should undergo SLNB, being the lesions as better stratified as possible 
25
. 
SLNB is a unique technique to detect lymph node micrometastases and it has a 
much lower morbidity and adverse effects, when compared to elective 
lymphadenectomy 
44









. However this is undergoing a transformation and it proved to also be 
17 
 
effective in thin melanomas, when additional risk factors are present. These factors 
include ulceration and mitotic rate, which change the classification to T1b if present 
7,18
.  
Thin melanomas mitotically inactive (0 mitoses per mm
2
), which corresponds to 
the majority, have low probability of sentinel lymph node positivity. This percentage 
tends to rise with increasingly MR 
13
.  
In melanomas with depth ≤0,75mm the incidence of positive SLNB is less than 
5%. When depth is between 0.75–1.0 mm, the rate of positive sentinel nodes biopsy is 
around 5% and the prognosis for these 5% of the patients is much poorer than in 
patients with a negative sentinel node biopsy. In these tumors cluster, when mitotic rate 
of 1/mm
2
 or higher is present, SLNB to search for lymph node micrometastasis may be 
proposed to the patient, especially if other risk factors are present 
7,21,35
. These risk 
factor for biopsy positivity comprehend: vascular and lymphatic invasion, positive 
margins and youngsters 
21
. 
MR has, therefore, been used as indicative to proceed with SLNB, even before it 
was added to the AJCC staging system. It is used due to a proved relation of positivity 
amidst the two factors in previous studies. Contradictorily, recent studies have 
increasingly shown the data is currently insufficient to determine the risk of clinically 
occult lymph node metastasis, solely by using MR 
7,13
 and some determine it should not 
therefore be indicative to proceed 
46
. There are various reasons for these two visions. 
One example is: SLNB may be positive in cases where the tumors had higher Breslow 
thickness, which may overshadow the MR prognostic value. It was discovered MR is 
highly predictive of SLNB positivity in intermediate thickness MM (1-4 mm). The need 
for more studies proving this relation is unanimous 
44,46
.  
Previous studies have shown no survival improvements when SLNB is performed, 
namely in thin melanomas 
7,33,44
. Currently it is not advisable to perform this procedure 
in melanomas ≤0,75mm deep, staged as IA or IB 
13
, given the low yield and cost 
effectiveness 
7
. In the 4
th
 Interdisciplinary Melanoma/ Skin Cancer Centers Meeting it 
was suggested by Daniel Coit that SLNB costs around 10,000 dollars per patient  to 
identify one unpreventable death in consequence of metastatic melanoma 
7
. 
Moreover it is important to remember that, besides the monetary implications, this 
procedure is not free of complications, namely because nearly 80% of the patients who 
undergo this procedure have negative biopsies. Common complications include: 
18 
 
infection, hematoma formation, sensory abnormalities, lymphedema, thrombophlebitis 
7,44
. 
Currently SLNB is performed in non-thin MM (Breslow thickness >1mm), as it 
was proved to relate with a risk of 10% of nodal invasion 
25
.This risk is around 5% in 
thinner MM 
35
, so this procedure is only considered when more risk factors are present, 
as pointed before. For instance, when ulceration is present, it is recommended by the 
AJCC that even tumors thinner than 0,75 mm should be referred for SLNB, as this 
complicates the correct measurement of Breslow thickness 
44
.  
Although some patients with T1b MM are suggested to undergo SLNB, it should 
be made considering all the adverse variables present. It is not mandatory, not even 
recommended, that all T1b MM patients are subjected to such technique 
25,26
. 
Concluding, as recommended by the AJCC, mitotic rate by itself should not be 





According to AJCC, the determination of mitotic figures for TNM is only 




Nonetheless, there are some mitoses’ (and consequently proliferation’s) specific 
markers, namely antigen Ki-67 and M-phase antibodies (phosphorylated histone H3 - 
anti-pHH3; mitotic protein monoclonal 2 - MPM-2), which might show higher counts of 
mitotic figures than H&E 
2,17,47
. 
Antigen Ki-67 is a sensitive marker of proliferation and cell growth that stains 
positive in 13-30% of the cells in MM but in less than 5% in benign melanocytic 
lesions. It is even considered a statistically significant and independent prognostic 
factor. However, it is not specific for mitoses in melanocytic cells and, therefore, it 
might overestimate mitotic index when other proliferative cells are present, as can 
happen with a vast inflammatory infiltrate around the tumor. In these cases, a double 
staining with Ki-67 and, for instance, MART-1 (melanoma antigen recognized by T 
cells) might be used to specifically stain mitoses in melanocytic lineage 
2,47,48
. 
Monoclonal antibody for pHH3 identifies mitoses in all stages, including 
prophase, and has been applied in other tumors, like meningiomas or astrocytomas, for 
19 
 
the same purpose. Mitotic figures were easily observed at 10x or 20x magnification, 














Casper et al 
30
 showed, comparing to H&E-stained sections, a mean increase of 
243% mitotic figures in tissue sections stained using anti-pHH3, in which 100% MM 
had mitoses present 
13,30
. These results present an intensification of sensitivity and 
sensibility for mitoses, with reduced observation time, when compared with H&E, 
where some would go unidentified. Therefore, in studies using anti-pHH3 stain, a MR 
≥2 mitoses/mm
2
 corresponded to ≥1/mm
2
 in H&E, therefore defining T1b stage 
13,35
. 
Probably, with increased use of immunohistochemical markers, T1b stage as we know it 
would lose its significance 
35
. 
Advantages of using immunohistochemistry directed to mitoses, namely anti-













Table 3: Advantages of 
immunohistochemistry (Anti-pHH3) 
Easier distinction of mitotic figures from 
apoptosis 
Pattern of distribution uncovering mitotic 
hot-spots 
Reduced average time needed to establish the 
mitotic count 




One of the objections addressing anti-pHH3 was the identification of mitoses that 
did not belong to melanocytes or confusion between epidermis-dermis junctional 
mitoses from superficial dermal ones. These mistakes will increase in a large scale the 
number of mitoses caught, turning uncertain the prognostic impact 
17,18,30
. 
These difficulties can be bypassed with a dual staining set, using for instance 
melanoma-associated antigen recognized by T-cells (Melan-A), marking melanocytes
30
. 
Recent reports used this dual staining and a correlation with prognosis was positively 
suggested 
18,36
. In a small study, Ottmann et al 
18
 showed that the increase in mitoses 
detection using anti-pHH3 disappeared when Melan-A immunostaining was added. This 
means the large increase in mitoses counting was, in this case, due to mitoses in other 
cells than melanocytes. They could not prove mitoses found by anti-HH3 influenced 
staging or prognosis for the lesion 
18
. 
Therefore, the conclusion is the routinely investigation for mitotic rate, 
particularly in thin melanomas, should be performed using H&E, taking into account 
only the dermal figures, as suggested by the AJCC. Anti-pHH3, always used as a double 
staining with a melanocytic marker such as Melan-A, should be restricted to staging 





It has been repeatedly shown that after MR introduction on the staging system in 
2009, a considerable percentage of patients classified with T1a MM shifted to T1b. 
Consequently, prognosis is considered worse and, for that reason, increasingly more 
patients are subjected to invasive techniques, namely SLNB, changing the previous 
conduct towards patients 
25
. 
It is still of vast importance to distinguish some details such as the significance of 
epidermal vs. dermal mitosis and their depth in the layers, as well as their morphology. 
Additionally it comes to our attention that not every melanoma included in T1a behaves 




One of the greatest defaults was that there are not enough prospective studies to 
dictate the reliability of the hot spot approach to mitotic rate in MM. Therefore, recent 
studies have invested in this matter and showed high reproducibility among 
pathologists, when the hot spot method is used 
13,25,26
. However, it is still doubtful how 
21 
 
thorough the section should observed and even how much sections should be made. It is 
recommended to search 5 contiguous fields but this pops up the question: “is this truly 
representative of the MR within the entire lesion?” Regarding one single melanoma, 
MR can be highly altered, just out of chance
7
. 
Actually, in a high percentage of cases, mitotic rate could not be accurately 
measured and got different appreciations by different observers 
17,20,33
. This can depend 
for example on how much time one invests in that section’s microscope observation, 
leaving the diagnosis to be a matter of chance instead of standardized scales 
17,20
. 
Normally mitoses can be observed in 30 to 120 minutes, being metaphase even shorter; 
in MM with atypical highly-ploidy cells, metaphase might be longer, which can 
increase MR
50
. There are, in fact, some challenges interpreting mitotic figures and that 
can be due to a various number of factors, namely, difficulty determining junctional or 
dermal mitosis, small and easily missed mitotic figures, confusion with another cell 
mitosis such as endothelial or keratinocytes (which are the most common cells in 
epidermis), with pyknotic nuclei or even with the population of infiltrative lymphocytes 
(inflammation) or numerous melanophages 
17,20,32,50
. Additionally, staging can be 
affected by how tissue sampling is collected and fixated, the system used to score 




When we are referring to a highly proliferative melanoma, even though some 
mitotic figures might not be actually from melanocytes, it does not make a huge 
difference. On the other hand, in a thin melanoma, mitoses are usually present in just 
one figure, demanding a careful and expandable search. In the latter it is much more 
difficult to discriminate whether that one mitotic figure found in so many fields is 
sufficient for changing classification for T1b 
17,19,50
. It has been reported to be an 
overestimating risk factor 
6
, because if the only mitotic figure present is misinterpreted 
(which can happen), it is changing, erroneously, the tumor from T1a stage to T1b and, 
consequently, changing patient’s management 
7,13,33
. 
In the case of Breslow depth, a micrometer is used to reduce interobserver 
variability. However, in determination of mitotic rate there is still not a tool to help 
reduce interobserver variability or precisely identify mitotic figures 
32
. It has to be 
studied the way to make hot spot technique and mitotic detection less abstract. 
22 
 
Additionally it has to be reviewed if one mitotic figure should change MM 
classification, especially since we can also find mitoses in hyperplasia processes or in 
common benign melanocytic nevi, in almost 50% if a specific immunohistochemical 
marker is used 
7,13,33,50
. Every process that grows is expected to show mitoses if one 
search for long enough. The mitotic figure itself is not a synonym of malignancy and, 
most often, it does not mean a poorer prognosis 
7
. 
Thus, it is clear there is not one characteristic in itself capable of differentiating 
among pigmented benign and malignant lesions 
5
. 
Besides, melanomas are malignant tumors supposedly growing every day. With 
immunohistochemical markers, nearly 100% of them have mitoses present. With this 
documented, it turns hard to understand why one mitotic figure, “possibly the only one 
in hundreds of sections” 
50
 can determine the change of classification to a poorer 
prognostic level and promote invasive and expensive procedures, for instance 
SLNB
30,50




As we could analyze, T1b stage, when together with other risk factors, is 
indicative for undergoing SLNB 
25,33
. Melanomas with Breslow thickness 0,5mm or 
lower are unlikely to show positivity for malignant cells in lymph node analysis and, 
even for those between 0,76-1,00mm, if only one mitosis is present, they are considered 
of low risk for nodal metastases. Therefore, not all patients with T1b MM should be 
submitted to this invasive technique 
7,13
. 
Doctors and pathologists need to choose which patient from IB stage should 
undergo SLNB 
13




Therefore, the extreme importance of correlating histological results with 
morphological and clinical context of the patient (including previous trauma, sun 
exposure, personal and family history, age or site of the lesion) before any practical 
decisions must be highlighted. Also it is extremely important we always recall the 
exceptions, for instance, neonatal and children’s melanoma, which is improbable but 
not impossible to appear 
4
. 
There are several methods to help clinicians diagnose melanoma, including 
cytological features, in which mitoses can be integrated. However, none of these 
methods are exclusive to melanoma and many can also be found in melanocytic benign 
23 
 
lesions, as conventional nevi. However, usually, they are less pronounced than generally 
seen in malignant lesions. For instance, dermal mitoses have been found to be 




Also, prognosis is dependent on other characteristics besides the primary tumor 
itself (tumor thickness, ulceration, and mitosis), such as the hosts’ immune 
response
22,52
; for example, the presence of tumor-directed T-cell responses are 
associated with a favorable outcome in metastatic melanoma 
22
. Moreover, we should 
take into consideration that, like in any other condition, there are factors other than 
those referred in AJCC influencing patient prognosis, namely general state of health, 
psychological stability or even social network 
20
. 
This is why diagnosis can not be based just on checklists but, instead, it should be 





Clinical and histological diversity in primary cutaneous MM seems to be 
associated with a heterogeneity not only phenotypical but genotypical as well. 
Investigation to separate patients into different groups may be interesting, in order to 
individualize both prognosis and treatment 
52
. 
A new prognostic variable is of practical use when it is significant statistically, 
easily assessed, reliably detected and with a great impact in the prognosis 
20
. 
MR is considered objective in characterizing MM tumors for their own biology. 
Therefore, an urgent uniformity for the method of measurement and effort required to 
find mitosis is needed, to render the staging more accurate and reliable among diverse 
technicians 
26,35
, considering one mitotic figure can have the absolute power of shifting 
patient’s management, surgically and medically 
30
. 
For the future, some more studies need to be accomplished to specifically 
determine mitotic rate power and standardized use of immunohistochemical stains, 
defining the consequences in the attitude towards patients. An automatized recognition 
of mitotic figures with image analysis systems might be a way to go, even though some 
of the errors currently made could happen and should be overcome before implementing 
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